Overview

Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.

Status:
Terminated
Trial end date:
2004-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the two studies is to determine whether an experimental therapy using a photoactive drug, verteporfin, in combination with direct light exposure of basal cell carcinoma of the skin can safely eliminate these skin tumors.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
QLT Inc.
Collaborator:
Novartis
Treatments:
Verteporfin
Criteria
Inclusion Criteria:

- Currently has at least 3 eligible BCC skin tumors that have never been treated

- Is willing to have these tumor sites surgically removed

Exclusion Criteria:

- Has xeroderma pigmentosum

- Has BCC tumors that are the result of prior radiotherapy or immunosuppression due to
an organ transplant

- Is immunosuppressed

- Has abnormal liver function

- Is receiving systemic chemotherapy or has received chemotherapy within the last two
years